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Background
Vaccine-induced memory T cells present in mucosal sur-
faces may provide a potent barrier to infection with HIV,
could reduce HIV transmission, and/or ameliorate pro-
gression to AIDS. All-trans retinoic acid (ATRA) has been
shown to induce the expression of gut-homing receptors
on T cells during activation in vitro.
Methods
We investigated the use of ATRA (300 μg. intraperitoneal)
as an in vivo adjuvant during vaccination of mice with ade-
novirus expressing the LCMV glycoprotein (gp) as a
model antigen (Ad5 gp, 5 × 108 pfu, intramuscular) on the
formation and migration of antigen-specific T cells to
mucosal sites. To have a definable population for tracking
T cell responses, we adoptively transferred 103 congeni-
cally marked P14 TCR-transgenic CD8 T cells, which are
specific for the gp33-41 epitope, prior to immunization.
Results
ATRA treatment during priming with Ad5gp did not sys-
temically alter the activation or magnitude of the primary
gp33-41 specific CD8 T response, but did increase the
number of effector and (and subsequently memory) T
cells that localized to mucosal associated tissues. How-
ever, ATRA during priming did result in a higher propor-
tion of systemic central-memory phenotype T cells. T cells
primed in the presence of ATRA proliferated more during
heterologous boosting with modified vaccinia Ankara
expressing gp (MVAgp, 107 pfu, intraperitoneal) and
exhibited increased gut homing. Mice receiving ATRA dur-
ing vaccination were also more resistant to vaginal
mucosa challenge with vaccinia virus (VVgp, 6 × 106 pfu)
and this correlated with increased gp33–41 specific T cell
responses at these sites.
Conclusion
ATRA administration during priming in this mouse model
resulted in increased mucosal and central memory T cells
that were able to better control virus challenge. Thus,
ATRA may be an ideal adjuvant for inclusion into vaccina-
tion strategies for humans against mucosally transmitted
pathogens such as HIV. This study is supported by the Bill
& Melinda Gates Foundation.
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